Cygnus Technologies, part of Maravai LifeSciences, is a leading brand in the biopharmaceutical industry, specializing in the detection and characterization of impurities, such as host cell proteins. With a 20-year history of quality and innovation, Cygnus offers a wide range of products and services to support companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives, and gene therapies. Their product portfolio includes ELISA kits for the detection of host cell proteins, process-related impurities, and species-specific immunoglobulins.

They also offer antibodies for the detection of host cell proteins and process-related impurities. In addition, Cygnus provides solutions for host cell DNA detection and viral clearance, ensuring the safety of biotherapeutics prior to human trials and regulatory approval. What sets Cygnus apart is their commitment to innovation.

They have developed breakthrough technologies such as Antibody Affinity Extraction™ (AAE), which integrates Mass Spectrometry, AAE, and ELISA for improved bioprocess impurity detection. They also offer unique non-infectious mock virus particles through their MockV™ virus clearance kits, reducing the cost and risk associated with viral clearance studies. With their industry pioneer status and ISO-9001:2015 certified quality management systems, Cygnus is recognized for delivering best-in-class customer service and technical expertise.

Their goal is to ensure the safety and accelerate the development of biotherapeutics, making them a trusted partner in the biopharmaceutical industry